ReviewThe AAPS journal2009
A review of imaging agent development.
Review in The AAPS journal, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Photoredox Nucleophilic (Radio)fluorination of Alkoxyamines.Journal of the American Chemical Society · 2024Article
- Advances in PET imaging of cancer.Nature reviews. Cancer · 2023Review
- A carbon-11 labeled imidazo[1,2-American journal of nuclear medicine and molecular imaging · 2023Article
- Preclinical Evaluation of a Humanized, Near-Infrared Fluorescent Antibody for Fluorescence-Guided Surgery of MUC16-Expressing Pancreatic Cancer.Molecular pharmaceutics · 2022Article
- Investigation of Radiotracer Metabolic Stability In Vitro with CYP-Overexpressing Hepatoma Cell Lines.Cells · 2022Article
- Molecular Endoscopy for the Diagnosis and Therapeutic Monitoring of Colorectal Cancer.Frontiers in oncology · 2022Review
- The Development ofRadiology. Imaging cancer · 2022Review
- Review
- Different PEG-PLGA Matrices Influence In Vivo Optical/Photoacoustic Imaging Performance and Biodistribution of NIR-Emitting π-Conjugated Polymer Contrast Agents.Advanced healthcare materials · 2021Article
- PET/CT Technology in Adult Zebrafish: A Pilot Study Toward Live Longitudinal Imaging.Frontiers in medicine · 2021Article
- PET Radiotracers for CNS-Adrenergic Receptors: Developments and Perspectives.Molecules (Basel, Switzerland) · 2020Review
- Modular Medical Imaging Agents Based on Azide-Alkyne Huisgen Cycloadditions: Synthesis and Pre-Clinical Evaluation ofChemistry (Weinheim an der Bergstrasse, Germany) · 2020Article
- Image-guided tumor surgery: The emerging role of nanotechnology.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
- Rapidly (and Successfully) Translating Novel Brain Radiotracers From Animal Research Into Clinical Use.Frontiers in neuroscience · 2020Review
- Imaging of T-cells and their responses during anti-cancer immunotherapy.Theranostics · 2019Review
- Neurotheranostics as personalized medicines.Advanced drug delivery reviews · 2019Review
- Chemical and photonic interactionsMaterials today. Bio · 2019Article
- Performing radiosynthesis in microvolumes to maximize molar activity of tracers for positron emission tomography.Communications chemistry · 2018Article
- Clinical applications of chemical exchange saturation transfer (CEST) MRI.Journal of magnetic resonance imaging : JMRI · 2018Review
- Biomathematical screening of amyloid radiotracers with clinical usefulness index.Alzheimer's & dementia (New York, N. Y.) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This educational review highlights the processes, opportunities, and challenges encountered in the discovery and development of imaging agents, mainly positron emission tomography and single-photon emission computed tomography tracers. While the development of imaging agents parallels the drug development process, unique criteria are needed to identify opportunities for new agents. Imaging agent development has the flexibility to pursue functional or nonfunctional targets as long as they play a role in the specific disease or mechanism of interest and meet imageability requirements. However, their innovation is tempered by relatively small markets for diagnostic imaging agents, intellectual property challenges, radiolabeling constraints, and adequate target concentrations for imaging. At the same time, preclinical imaging is becoming a key translational tool for proof of mechanism and concept studies. Pharmaceutical and imaging industries face a common bottleneck in the form of the limited number of trials one company can possibly perform. However, microdosing and theranostics are evidence that partnerships between pharmaceutical and imaging companies can accelerate clinical translation of tracers and therapeutic interventions. This manuscript will comment on these aspects to provide an educational review of the discovery and development processes for imaging agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.